between anti-CarPA and ΔDAS28 showed association only with ΔDAS28 from baseline to M6 (p=0.005). In this period, the positive patients showed less decrease of DAS28 than the negative patients. This was independent of all the variables mentioned above and of the initial DAS28. As a result of this association, 20.5% of the anti-CarPA positive patients reached remission at M6, in comparison with 34.6% of the negative patients. In contrast, ΔDAS28 from M6 to M12 and from M12 to M24 were small and not associated with anti-CarPA.

Conclusions: Anti-CarPA were associated with high disease activity at presentation and with less improvement in the first 6 months of follow-up in EA patients. These results reinforce the possibility that anti-CarPA could be useful in the clinic as prognostic biomarkers.

Acknowledgements: Supported by grants PI14/01651 and RD16/0012/0014/0011/0012 of the Instituto de Salud Carlos III (Spain) that are partially financed by the ERDF

Disclosure of Interest: None declared


Abstract SAT0085

RELATIONSHIP BETWEEN SERUM CALPROTECTIN, DISEASE ACTIVITY PARAMETERS AND THE 7-Joint ULTRASOUND SCORE IN RHUMATOID ARTHRITIS

M. Turgut1, A. B. Kelesoglu Dincer1, E. M. Yayı1, S. Serdar1, U. Ebru 2, G. Kinikli1, M. T. Turgay1, M. Torgutalp1, G. E. Aydemir Guloksuz1, S. Serdar1, U. Ebru 2, G. Kinikli1, M. T. Turgay1, A. Ates1.

1Rheumatology; 2Microbiology, Ankara University Faculty of Medicine, Ankara, Turkey

Background: Calprotectin may be a sensitive biomarker of rheumatoid arthritis (RA) disease activity.

Objectives: In this study we aimed to investigate whether calprotectin is a better biomarker than known inflammation markers for predicting clinical activity and ultrasound parameters in patients with RA.

Methods: A total of 80 RA patients were underwent to clinical (swollen joint count, tender joint count), disease activity score-DAS28, simplified disease activity index-SDAI and clinical disease activity index-CDAI and ultrasound (German US7) examination. Correlation of clinical, laboratory and ultrasound measures were analyzed using Spearman's correlation coefficient. The RA patients were divided into two subgroups according to their DAS28-ESR (erythrocyte sedimentation rate) score; group 1 (DAS28 <3.2 remission and low activity), group 2 (DAS28 ≥3.2 moderate and high activity), respectively. Thirty healthy controls were simultaneously studied.

Results: The serum calprotectin levels of the RA patients were significantly higher than those of healthy controls (96.3±45.9, 54.7±50.0, respectively; p<0.001). Distribution of age (years; 57.2±9.6, 53.9±10.5, respectively; p=0.115) and sex (female; 78.8%, 70%, respectively, p=0.336) between these groups were similar. The clinical, laboratory and ultrasound characteristics of the patients are shown in table 1. The calprotectin levels were 74.8±45.5 in group 1 (n=37) and 114.7±37.9 in group 2 (n=43) (p<0.001). The association between calprotectin and scores of DAS28-ESR are shown in figure 1A. Serum calprotectin was significantly associated with DAS28-ESR, DAS28-CRP (C-reactive protein), SDAI, CDAI, CRP, US7 parameters. We also found a moderate to strong correlation of US7 score with DAS28-ESR, DAS28-CRP, SDAI, CDAI, CRP and ESR (table 2). The correlation between calprotectin and US7 is shown in figure 1B.

Abstract SAT0086

EVALUATION OF DIAGNOSTIC PERFORMANCE OF MAGNETIC RESONANCE IMAGING (MRI) AND ULTRASOUND (US) TOWARD EARLY RA

A. Takatani1, M. Tamai1, N. Ohk2, Y. Nakashima1, Y. Endo1, S. Tsugi1, T. Shimizu1, M. Umeda1, S. Fukui1, R. Sumiyoshi1, A. Nishino1, T. Koga1, S.-Y. Kawashiri1, N. Iwamoto1, T. Igar1, K. Ichinose1, K. Arima1, H. Nakamura1, T. Origuchi1, S. Sato1, M. Uetani1, A. Kawakami1, 1Department of Immunology and Rheumatology; 2Department of Radiological Sciences; 3Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences; 4Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan

Background: We previously reported that the presence of autoantibodies, magnetic resonance imaging (MRI) bone oedema, ultrasound (US) power Doppler (PD) ≥2 grade 2 articular synovitis are indispensable markers to predict the development of RA from undifferentiated arthritis whereas combination analysis used by the above variables, focusing on very early phase of arthritis, remains to be done in our cohort.

Objectives: To investigate and re-confirm the diagnostic performance of autoantibodies, MRI findings and US findings toward early RA from NAGASAKI EARLY ARTHRITIS COHORT.

Methods: One hundred and three patients, suffering arthralgia less than 6 months and examined by both MRI and US of wrist and finger joints, were selected from NAGASAKI EARLY ARTHRITIS COHORT dating from September 2009 to August 2017. US were evaluated by synovitis score of semi-quantitative manner by gray-scale (GS) and power Doppler (PD) proposed from EULAR. In MRI, synovitis, bone oedema and bone erosion were assessed by the Rheumatoid Arthritis Magnetic Resonance Imaging Scoring system (RAMRIS). After univariate analysis, multivariate analysis was employed to clarify the diagnostic predictors of early RA.

Results: Median of age was 60 years and that of symptomatic duration was 2 months. Female was 68.9%, positive rate of RF was 64.7% and that of ACPA was 47.1%. Total GS score was 4.0, total PD score 2.0, MRI synovitis score 3.0, MRI bone oedema score 0, MRI bone erosion score 0. Seventy patients were diagnosed as early RA during follow-up periods. A univariate analysis showed ACPA, CRP, MMP-3, fulfilment of 2010 ACR/EULAR criteria, MRI synovitis score, MRI bone oedema score, total GS score, total PD score and PD ≥2 grade 2 articular synovitis were associated with early RA. Multivariate analysis revealed ACPA and PD ≥2 grade 2 articular synovitis at any joints were independent predictors toward diagnosis of early RA.

Table 2 Spearman’s rank correlation coefficients between calprotectin, US7 scores and other variables:

<table>
<thead>
<tr>
<th></th>
<th>ESR</th>
<th>CRP</th>
<th>DAS28-ESR</th>
<th>DAS28-CRP</th>
<th>CDAI</th>
<th>SDAI</th>
<th>US7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calprotectin</td>
<td>0.361</td>
<td>0.306</td>
<td>0.327</td>
<td>0.315</td>
<td>0.381</td>
<td>0.395</td>
<td>0.397</td>
</tr>
<tr>
<td>ESR</td>
<td>0.494</td>
<td>0.461</td>
<td>0.306</td>
<td>0.286</td>
<td>0.561</td>
<td>0.561</td>
<td>0.561</td>
</tr>
<tr>
<td>CRP</td>
<td>0.512</td>
<td>0.477</td>
<td>0.315</td>
<td>0.315</td>
<td>0.556</td>
<td>0.556</td>
<td>0.556</td>
</tr>
<tr>
<td>DAS28-ESR</td>
<td>0.828</td>
<td>0.846</td>
<td>0.695</td>
<td>0.695</td>
<td>0.923</td>
<td>0.923</td>
<td>0.923</td>
</tr>
<tr>
<td>DAS28-CRP</td>
<td>0.856</td>
<td>0.924</td>
<td>0.901</td>
<td>0.901</td>
<td>0.956</td>
<td>0.956</td>
<td>0.956</td>
</tr>
</tbody>
</table>

Conclusions: The results of our study support an additional role of calprotectin in assessing inflammatory activity in patients with RA. Therefore, the combination of serum calprotectin levels and the US7 score could be a simple and practical assessment approach for detection of RA disease activity.

Disclosure of Interest: None declared

Background: The use of a treat-to-target (T2T) strategy for the management of rheumatoid arthritis (RA) leads to better outcomes but requires the regular use of disease activity measures (DAMs) to make clinical decisions. The optimal DAMs that should be used for this purpose have yet to be determined.

Objectives: To assess the utility of various DAMs for clinical decision making at a rheumatology clinic implementing a T2T strategy, following the initiation of Tofacitinib (tofc) and anti-tumour necrosis factor (ant-TNFs) agents.

Methods: Patients at a community based rheumatology clinic (authors) underwent rheumatoid arthritis (RA) can detect synovial inflammation with higher sensitivity compared to physical examination alone. Not all rheumatologists have adopted the use of MSUS in their daily practice.

Methods: Data from patients; 18 years old with a confirmed diagnosis of RA who had an index visit in the Corona RA Registry from 01/01/2012 to 12/31/2015 with ≥12 months of follow-up were stratified into 2 groups: patients whose physicians use MSUS frequently—ie, in >50% of their patient encounters—(MSUS group) and patients whose physicians do not use MSUS at all (No-MSUS group).

Frequency of MSUS can be recorded and updated by the rheumatologist in the registry questionnaires at every Corona visit. The index visit was the first visit in which the physician reported the frequency of MSUS use. Outcomes included mean Clinical Disease Activity Index (CDAI) and the proportion of patients in low disease activity (LDA)/remission (CDAI ≤ 10) at each time point and were evaluated at index and 1, 2, and 3 years post-index. Comparisons between groups were made using 2-sample t-tests for mean CDAI and Chi-square tests for achievement of LDA/remission.

Results: 21 physicians reported using MSUS frequently compared with 111 who did not use MSUS at all. 54% of their patients met the criteria for analysis; 1018 (18.7%) were in the MSUS group and 4428 (81.3%) were in the No-MSUS group. At the index visit, the MSUS group was younger (mean age 57.7 years vs 59.8 years, p<0.01) and had shorter disease duration (mean 8.7 years vs 11.6 years, p<0.01) compared with the No-MSUS group. At the index visit, the MSUS group had lower mean CDAI (9.7 vs 12.6, p<0.01) and a greater proportion of patients in LDA/remission (64.9% vs 56.8%, p<0.01) compared with the No-MSUS group; these differences were also present at 1, 2, and 3 years post-index (figure 1).

Over the past four years, Thirty nine patients at this clinic were determined to be under inadequate control and were started on tofc. Also, the forty patients started on anti-TNFs at the clinic were assessed for comparison. The two groups of patients had similar demographics with a combined average duration of clinical disease found to be >10 years. Sixty eight% of these patients were female, and 85% of patients were rheumatoid factor positive. Table I shows that all of the DAMs listed resulted in significant clinical responses with the exception that following the institution of tofc, the MBDA did not result in clinically significant improvement. When individual biomarkers from the MBDA were analysed, anti-TNFs therapy lead to significant reduction in six of twelve biomarkers (IL-6, TNF-R1, TNF-R2, MMP-2, SSA and SRP) whereas treatment with tofc lead to significant reduction of two (VCAM and Resisten) and borderline reduction in two (IL-6 and TNF-R1) and a significant increase in one (Leptin).

Conclusions: A greater percentage of patients whose physicians use MSUS within LDA/remission over time. Average disease activity of these patients was lower compared with patients whose physicians did not use MSUS. This pattern was observed at 4 different time points over a 3 year period.

REFERENCE:

Acknowledgements: Corona has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Horizon Pharma USA, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Pfizer Inc, Roche, UCB and Valeant. The design, study conduct, and financial support for the study was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract.

Medical writing services provided by Joann Hettasch of Fishawack Communication and funded by AbbVie.

Disclosure of Interest: None declared


Over the past four years, Thirty nine patients at this clinic were determined to be under inadequate control and were started on tofc. Also, the forty patients started on anti-TNFs at the clinic were assessed for comparison. The two groups of patients had similar demographics with a combined average duration of clinical disease found to be >10 years. Sixty eight% of these patients were female, and 85% of patients were rheumatoid factor positive. Table I shows that all of the DAMs listed resulted in significant clinical responses with the exception that following the institution of tofc, the MBDA did not result in clinically significant improvement. When individual biomarkers from the MBDA were analysed, anti-TNFs therapy lead to significant reduction in six of twelve biomarkers (IL-6, TNF-R1, TNF-R2, MMP-2, SSA and SRP) whereas treatment with tofc lead to significant reduction of two (VCAM and Resisten) and borderline reduction in two (IL-6 and TNF-R1) and a significant increase in one (Leptin).

Conclusions: A greater percentage of patients whose physicians use MSUS within LDA/remission over time. Average disease activity of these patients was lower compared with patients whose physicians did not use MSUS. This pattern was observed at 4 different time points over a 3 year period.